Sovereign sells Xendo to ProPharma Group
UK private equity firm Sovereign Capital Partners has exited investment in Xendo – an independent consultancy and project management organisation in the of (bio)pharmaceutical products, medical devices and healthcare space – to ProPharma Group, a portfolio company of US-based Linden Capital Partners. This is Sovereign’s third exit in recent weeks